From a data base of 1724 patients (p) with MBC, we selected a group of 612 p (35.5%) treated with CT as only first-line treatment. CT was chosen in the basis of clinical criteria.There were 609 women (99.5%), with mean age of 50 years (range 24–89). Forty-eight percent had received adjuvant treatment after the local treatment of the primary (median of disease free survival until metastatic disease: 14 months em), range 0–180) and a 73%, (447 p) had suppressed ovarian function.Metastatic disease was present in an isolated organ in 48%. of p. Lymph-node involvement was present in 43% of p, skin in 39%, lung in 45% (34% nodular and 11% lymphangitic), bone in 28%, pleura in 18%, liver in 11%, brain in 2% and other organs in 2%.Overall response rate was 36.6% (13.4% CR and 23.2% PR). There were no changes (NC) in 21.7% and progressive disease (PD) in 41.7%. With a median follow-up for CR of 6m (2–192),65 p (79%) have relapsed. Median duration of CR was 20m (CI 95% 16–24). Most of relapsed patients received a second line treatment.After a median follow-up for survival of 14m (2–219),439 p (68.5%) have died. Median survival (and 95% CI) were 20m (18–22) for the whole series, 42m (29-53) for CR, 21m (17–25) for PR, 24m (19–29) for NC and 11m (9–13) for Po. There were statistically significant differences in survival between CR vs PR, CR vs NC, CR vs PD, PR vs PD andNC vs PD.In conclusion we have observed long survival in selected patients who obtain CR after standard doses of CT.